6,359 Shares in United Therapeutics Corporation $UTHR Purchased by Partners Capital Investment Group LLP

Key Points

• Partners Capital Investment Group LLP acquired 6,359 shares in United Therapeutics Corporation, valued at approximately $1.96 million, marking a new stake for the group in the first quarter.
• United Therapeutics stock is currently down 2.2%, with shares opening at $306.48, and the company has a market cap of $13.83 billion.
• Despite the stock's decline, several analysts maintain a positive outlook, with reports indicating an average price target of $382.00 and multiple "buy" ratings from various firms.

Partners Capital Investment Group LLP bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,359 shares of the biotechnology company's stock, valued at approximately $1,960,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. XTX Topco Ltd purchased a new stake in shares of United Therapeutics during the first quarter worth approximately $313,000. Allianz Asset Management GmbH boosted its stake in United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after purchasing an additional 33,254 shares during the last quarter. LPL Financial LLC grew its holdings in shares of United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after buying an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after buying an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of United Therapeutics in the first quarter worth about $227,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 2.2%

Shares of United Therapeutics stock opened at $306.48 on Thursday. The firm has a market cap of $13.83 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 4.75 and a beta of 0.57. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The business's fifty day simple moving average is $295.95 and its 200-day simple moving average is $308.25.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the firm posted $5.85 earnings per share. The firm's quarterly revenue was up 11.7% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on UTHR shares. UBS Group upped their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. HC Wainwright set a $400.00 price target on United Therapeutics and gave the company a "buy" rating in a research report on Thursday, July 31st. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Finally, Bank of America cut their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $382.00.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $300.00, for a total value of $3,300,000.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $11,034,300. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,681 shares of company stock valued at $24,618,359 over the last 90 days. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.